The FINANCIAL — Roche announced on May 30 that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin (bevacizumab) and Tarceva (erlotinib) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results